- Home »
- Quarterly Results »
- Sanofi India Q1 Results Revenue Declines to ₹4,635 Million and Profit for the Period Falls to ₹1,032 Million
Sanofi India Q1 Results Revenue Declines to ₹4,635 Million and Profit for the Period Falls to ₹1,032 Million
Sanofi India Q1 Results show a 9.3% QoQ decline in revenue to ₹4,635 million, and a 24.5% QoQ drop in profit for the period to ₹1,032 million, reflecting increased operational costs and reduced sales.
by P Nandhini
Updated Aug 28, 2024
Table of Content
Sanofi India Q1 Results: Sanofi India announced its Q1 financial results for the fiscal year 2024-2025 on July 26, 2024. The company reported a revenue of ₹4,635 million for the quarter ended June 30, 2024, which represents a decrease of approximately 9.3% compared to ₹5,108 million in the previous quarter.
The decline in revenue is attributed to a drop in the sales of certain key products and higher operational costs. In terms of profitability, Sanofi India saw a decrease in profit before exceptional items and tax, which stood at ₹1,111 million for Q1 2024-2025, down by 15.4% from ₹1,312 million in Q4 2023-2024.
The company's profit for the period from continuing operations also fell to ₹1,032 million, a decrease of 26.5% compared to ₹1,366 million in the previous quarter. This dip in profitability highlights the challenges faced by the company amid changing market conditions and increased expenses.
For More Q1 results check our Twitter Page
Sanofi India Q1 Results 2024 - 2025
Here is a summary of Sanofi India's Q1 financial results for the fiscal year 2024-2025:
| Particulars | Quarter Ended 30.06.2024 | Quarter Ended 31.03.2024 | % Change (QoQ) |
|---|---|---|---|
| Revenue from Operations | ₹4,635 million | ₹5,108 million | -9.3% |
| Other Income | ₹48 million | ₹35 million | +37.1% |
| Total Income | ₹4,683 million | ₹5,143 million | -8.9% |
| Total Expenses | ₹3,572 million | ₹3,831 million | -6.8% |
| Profit Before Exceptional Items & Tax | ₹1,111 million | ₹1,312 million | -15.4% |
| Exceptional Items | -₹190 million | -₹267 million | +28.9% |
| Profit Before Tax | ₹921 million | ₹1,045 million | -11.9% |
| Tax Expense | ₹282 million | ₹298 million | -5.4% |
| Profit for the Period | ₹1,032 million | ₹1,366 million | -24.5% |
Source: Here
Sanofi India Current Market Overview
Sanofi India is currently trading at ₹6,755 per share, with a market capitalization of ₹15,557 crore. The stock has seen a high of ₹7,540 and a low of ₹4,235 recently. It has a Price-to-Earnings (P/E) ratio of 31.7, indicating how much investors are willing to pay for each unit of earnings.
The company offers a dividend yield of 2.47% and has strong financial returns, with a Return on Capital Employed (ROCE) of 71.1% and a Return on Equity (ROE) of 51.5%. The face value of the stock is ₹10.00.
| Metric | Value |
|---|---|
| Current Price | ₹6,755 |
| Market Capitalization | ₹15,557 Crore |
| 52-Week High | ₹7,540 |
| 52-Week Low | ₹4,235 |
| Stock P/E Ratio | 31.7 |
| Book Value | ₹298 |
| Dividend Yield | 2.47% |
| Return on Capital Employed (ROCE) | 71.1% |
| Return on Equity (ROE) | 51.5% |
| Face Value | ₹10.00 |
Quarterly Results
Here are Sanofi India's quarterly financial results for the end of 2023 and the first half of 2024:
| Metric | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|
| Sales (₹ Million) | 694 | 511 | 464 |
| Expenses (₹ Million) | 506 | 374 | 348 |
| Operating Profit (₹ Million) | 187 | 137 | 116 |
| Operating Profit Margin (OPM %) | 27% | 27% | 25% |
| Other Income (₹ Million) | 12 | 41 | 21 |
| Interest (₹ Million) | 0 | 0 | 0 |
| Depreciation (₹ Million) | 10 | 9 | 9 |
| Profit Before Tax (₹ Million) | 189 | 169 | 127 |
| Tax % | 27% | 19% | 19% |
| Net Profit (₹ Million) | 138 | 137 | 103 |
| EPS (₹) | 59.87 | 59.39 | 44.96 |
About Sanofi India
Sanofi India is a major player in the healthcare industry, operating as a subsidiary of the global pharmaceutical company Sanofi. Founded in 1956, the company has evolved through several name changes, starting as Hoechst Fedco Pharma and eventually becoming Sanofi India.
With manufacturing sites in Hyderabad and Goa, Sanofi India produces a wide range of medicines, including tablets, capsules, and creams, adhering to strict international quality standards.
The company’s products are not only used within India but are also exported to several countries, ensuring high-quality healthcare solutions for diverse markets.
Visit our site for more Q1 results.
Sanofi India Q1 Results - FAQs
1. What are Sanofi India’s Q1 2024-2025 results?
Sanofi India reported a revenue of ₹4,635 million and a profit of ₹1,032 million.
2. When were Sanofi India’s Q1 financial results announced?
The results were announced on July 26, 2024.
3. What was Sanofi India’s revenue for Q1 2024-2025?
Sanofi India’s revenue was ₹4,635 million.
4. How much did Sanofi India’s revenue decrease in Q1 2024-2025?
Sanofi India’s revenue decreased by 9.3% compared to the previous quarter.
5. What was Sanofi India’s profit before exceptional items and tax in Q1 2024-2025?
Sanofi India’s profit before exceptional items and tax was ₹1,111 million.
6. What was Sanofi India’s profit for the period in Q1 2024-2025?
Sanofi India’s profit for the period was ₹1,032 million.
7. What was Sanofi India’s total income for Q1 2024-2025?
Sanofi India’s total income was ₹4,683 million.
8. What were Sanofi India’s total expenses in Q1 2024-2025?
Sanofi India’s total expenses were ₹3,572 million.
9. What was the amount of other income for Sanofi India in Q1 2024-2025?
Sanofi India’s other income was ₹48 million.
10. What was Sanofi India’s tax expense in Q1 2024-2025?
Sanofi India’s tax expense was ₹282 million.